Differences in vanadocene dichloride and cisplatin effect on MOLT-4 leukemia and human peripheral blood mononuclear cells
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
22530915
DOI
10.2174/157340612801216364
PII: MC-EPUB-20120424-009
Knihovny.cz E-zdroje
- MeSH
- buněčné linie MeSH
- buněčný cyklus účinky léků MeSH
- cisplatina farmakologie MeSH
- leukemie farmakoterapie MeSH
- leukocyty mononukleární účinky léků MeSH
- lidé MeSH
- průtoková cytometrie MeSH
- sloučeniny vanadu farmakologie MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- cisplatina MeSH
- sloučeniny vanadu MeSH
- vanadocene dichloride MeSH Prohlížeč
Modern chemotherapy is interested in developing new agents with high efficiency of treatment in low-dose medication strategies, lower side toxicity and stronger specificity to the tumor cells. Vanadocene dichloride (VDC) belongs to the group of the most promising metallocene antitumor agents; however, its mechanism of action and cytotoxicity profile are not fully understood. In this paper we assess cytotoxic effects of VDC in comparison to cisplatin using opposite prototype of cells; human peripheral blood mononuclear (PBMCs) cells and human acute lymphoblastic leukemia cell line (MOLT-4). Our findings showed cytotoxic effect of VDC on leukemia cells, but unfortunately on human peripheral blood mononuclear cells as well. VDC induces apoptosis in leukemia cells; the induction is, however, lower than that of cisplatin, and in contrary to cisplatin, VDC does not induce p53 up-regulation. Cytotoxic effect of VDC on leukemia cells is less pronounced than that of cisplatin and more pronounced in PBMCs than in MOLT-4 cells.
Citace poskytuje Crossref.org